Loading...
XNAS
SLGL
Market cap204mUSD
May 06, Last price  
7.35USD
1D
66.29%
1Q
865.83%
IPO
-40.77%
Name

Sol Gel Technologies Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
131.76
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.68%
Rev. gr., 5y
64.50%
Revenues
2m
-59.98%
000174,000129,00022,904,0008,771,00031,272,0003,883,0001,554,000
Net income
-27m
L+100.25%
-4,848,000-9,660,000-20,771,000-31,568,000-32,203,000-24,609,000-27,401,0004,358,000-13,602,000-27,238,000
CFO
-18m
L+86.95%
-4,830,000-8,044,000-18,495,000-24,089,000-23,467,000-22,500,000-25,241,000-7,691,000-9,484,000-17,730,000
Earnings
May 19, 2025

Profile

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
URL
http://www.sol-gel.com
IPO date
Feb 01, 2018
Employees
55
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,554
-59.98%
3,883
-87.58%
Cost of revenue
54,455
32,809
Unusual Expense (Income)
NOPBT
(52,901)
(28,926)
NOPBT Margin
Operating Taxes
(1,321)
Tax Rate
NOPAT
(52,901)
(27,605)
Net income
(27,238)
100.25%
(13,602)
-412.12%
Dividends
Dividend yield
Proceeds from repurchase of equity
21,542
15
BB yield
-71.97%
-0.01%
Debt
Debt current
447
718
Long-term debt
2,859
826
Deferred revenue
Other long-term liabilities
915
1,032
Net debt
(35,974)
(33,370)
Cash flow
Cash from operating activities
(17,730)
(9,484)
CAPEX
(134)
(171)
Cash from investing activities
(9,742)
1,699
Cash from financing activities
21,810
15
FCF
(46,702)
(30,453)
Balance
Cash
37,996
33,626
Long term investments
1,284
1,288
Excess cash
39,202
34,720
Stockholders' equity
(219,529)
(192,427)
Invested Capital
260,741
236,444
ROIC
ROCE
EV
Common stock shares outstanding
27,087
23,129
Price
1.11
-75.77%
4.56
-38.38%
Market cap
29,931
-71.62%
105,465
-39.52%
EV
(6,043)
72,095
EBITDA
(52,559)
(28,364)
EV/EBITDA
0.11
Interest
1,321
Interest/NOPBT